These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 39373900)

  • 21. Enhancing prognostication and treatment response evaluation in primary CNS lymphoma with 18F-FDG-PET/CT.
    Oh M; Cho H; Park JE; Kim HS; Go H; Park CS; Lee SW; Song SW; Kim YH; Cho YH; Hong SH; Kim JH; Lee DY; Ryu JS; Yoon DH; Kim JS
    Neuro Oncol; 2024 Dec; 26(12):2377-2387. PubMed ID: 39097777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Role of 18F-FDG PET/CT on Staging and Prognosis in Patients with Small Cell Lung Cancer.
    Zer A; Domachevsky L; Rapson Y; Nidam M; Flex D; Allen AM; Stemmer SM; Groshar D; Bernstine H
    Eur Radiol; 2016 Sep; 26(9):3155-61. PubMed ID: 26685851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer.
    Shastry M; Jacob S; Rugo HS; Hamilton E
    Breast; 2022 Dec; 66():169-177. PubMed ID: 36302269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of total metabolic tumour volume and therapy-response assessment by [
    Annovazzi A; Ferraresi V; Rea S; Russillo M; Renna D; Carpano S; Sciuto R
    Eur Radiol; 2022 May; 32(5):3398-3407. PubMed ID: 34779873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A preliminary investigation of the relationship between
    Hu L; Luo N; Li L; Qiu D; Hu X
    Front Oncol; 2023; 13():1171048. PubMed ID: 37397396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First-Line Chemo-Immunotherapy.
    Grambow-Velilla J; Seban RD; Chouahnia K; Assié JB; Champion L; Girard N; Bonardel G; Matton L; Soussan M; Chouaïd C; Duchemann B
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190152
    [No Abstract]   [Full Text] [Related]  

  • 27. Prognostic potential of integrated morphologic and metabolic parameters of pre-therapeutic [18F]FDG-PET/CT regarding progression-free survival (PFS) and overall survival (OS) in NSCLC-patients.
    Peters HA; Weiss D; Boschheidgen M; Mamlins E; Giesel FL; Fluegen G; Kirchner J; Antoch G; Jannusch K
    PLoS One; 2024; 19(7):e0307998. PubMed ID: 39074093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
    Cokmert S; Tanriverdi O; Karapolat I; Demir L; Bayoglu V; Can A; Akyol M; Yilmaz Y; Oktay Tarhan M
    J BUON; 2016; 21(6):1410-1418. PubMed ID: 28039701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET/CT as independent prognostic biomarkers of recurrence in resected breast cancer.
    Seban RD; Rouzier R; Latouche A; Deleval N; Guinebretiere JM; Buvat I; Bidard FC; Champion L
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3560-3570. PubMed ID: 33774685
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Girum KB; Rebaud L; Cottereau AS; Meignan M; Clerc J; Vercellino L; Casasnovas O; Morschhauser F; Thieblemont C; Buvat I
    J Nucl Med; 2022 Dec; 63(12):1925-1932. PubMed ID: 35710733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [
    Gui J; Li M; Xu J; Zhang X; Mei H; Lan X
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2308-2319. PubMed ID: 38467921
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy.
    Seban RD; Assié JB; Giroux-Leprieur E; Massiani MA; Bonardel G; Chouaid C; Deleval N; Richard C; Mezquita L; Girard N; Champion L
    Lung Cancer; 2021 Sep; 159():45-55. PubMed ID: 34311344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of pretreatment PET parameters in inoperable, node-positive NSCLC patients with poor prognostic factors undergoing hypofractionated radiotherapy: a single-institution retrospective study.
    Zinn AB; Kenndoff S; Holzgreve A; Käsmann L; Guggenberger JE; Hering S; Mansoorian S; Schmidt-Hegemann NS; Reinmuth N; Tufman A; Dinkel J; Manapov F; Belka C; Eze C
    EJNMMI Rep; 2024 Oct; 8(1):32. PubMed ID: 39375264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gastrointestinal Toxicity of Antibody Drug Conjugates (ADCs) in Metastatic Breast Cancer: A Pooled Analysis.
    Pedersini R; Buffoni M; Petrelli F; Ghidini A; di Mauro P; Amoroso V; Parati MC; Laini L; Cosentini D; Schivardi G; Ippolito G; Berruti A; Laganà M
    Clin Breast Cancer; 2024 Jul; 24(5):411-420. PubMed ID: 38734491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer.
    Jin P; Bai M; Liu J; Yu J; Meng X
    Front Immunol; 2022; 13():1004351. PubMed ID: 36341372
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Volumetric parameters from [
    Langen Stokmo H; Aly M; Bowitz Lothe IM; Borja AJ; Mehdizadeh Seraj S; Ghorpade R; Miao X; Hjortland GO; Malinen E; Sorbye H; Werner TJ; Alavi A; Revheim ME
    J Neuroendocrinol; 2022 Jul; 34(7):e13170. PubMed ID: 35729738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of baseline total metabolic tumour volume of
    Gong H; Li T; Li J; Tang L; Ding C
    EJNMMI Res; 2021 Jul; 11(1):64. PubMed ID: 34264417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The added prognostic values of baseline PET dissemination parameter in patients with angioimmunoblastic T-cell lymphoma.
    Gong H; Tang B; Li T; Li J; Tang L; Ding C
    EJHaem; 2023 Feb; 4(1):67-77. PubMed ID: 36819177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic Significance Of Sequential 18f-fdg Pet/Ct During Frontline Treatment Of Peripheral T Cell Lymphomas.
    Song GY; Jung SH; Ahn SY; Kim M; Ahn JS; Lee JJ; Kim HJ; Moon JB; Yoo SW; Kwon SY; Min JJ; Bom HS; Kang SR; Yang DH
    Korean J Intern Med; 2024 Mar; 39(2):327-337. PubMed ID: 38268194
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.
    Hurvitz SA; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Egorov A; Liu Y; Cathcart J; Bako E; Tecson K; Verma S; Cortés J
    ESMO Open; 2024 May; 9(5):102924. PubMed ID: 38796287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.